Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity first described in 1996 by Hinchey et al, most commonly associated with hypertensive encephalopathy, eclampsia in pregnant women, immunosuppressants and cytotoxic agents. In recent years, anti-angiogenic agents as a novel class of anticancer therapies have become a standard of care for certain tumours. Correspondingly, there have been an emerging number of case reports documenting PRES associated with these anti-angiogenic therapies. As the manifestations of PRES are often non-specific, but could rarely lead to permanent neurological disability or even death, it is crucial that physicians are aware of PRES in relation to anti-angiogenic therapy to promptly institute appropriate management to achieve the best outcomes for patients.
INTRODUCTION
Anti-angiogenic therapies are a novel class of agents that are increasingly incorporated in the armamentarium of anti-cancer therapies. These agents target the tumour vasculature 1 through binding of the pro-angiogenic ligands such as members of the vascular endothelial growth factor (VEGF) family and placental growth factor (PlGF) or through direct inhibition of the VEGF receptors on endothelial cells. Currently, several anti-angiogenic agents have been licensed 2 , these include bevacizumab (anti-VEGF monoclonal antibody for colorectal, renal and ovarian cancer, glioblastoma multiforme, lung adenocarcinoma), aflibercept 3 (recombinant fusion protein that traps VEGF and PlGF for colorectal cancer), ramucirumab 4 (anti-VEGF receptor monoclonal antibody for gastric cancer), sunitinib (small molecule tyrosine kinase inhibitor of VEGF receptor for renal cancer, pancreatic neuroendocrine and gastrointestinal stromal tumours), pazopanib (small molecule tyrosine kinase inhibitor of VEGF receptor for renal cancer and soft tissue sarcoma) and sorafenib (small molecule tyrosine kinase inhibitor of VEGF receptor for hepatocellular carcinoma, renal and thyroid cancer). As a consequence of targeting the VEGF pathway, these agents also have effects on the normal tissue vasculature 5 leading to hypertension, proteinuria 6 , arterial and venous thrombosis, haemorrhage 7 as well as fistulae 8 , reduced wound healing 9 and gastrointestinal perforations 10 .
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity first described in 1996 in patients with renal insufficiency, hypertension or immunosuppression by Hinchey et al 11 . Several conditions have also been associated with PRES, most commonly hypertensive encephalopathy, eclampsia in pregnant women, immunosuppressants and cytotoxic agents ( Table 1 ). In recent years, there have been several case reports of posterior reversible encephalopathy (PRES) associated with use of antiangiogenic therapies ( Table 2) .
PATHOPHYSIOLOGY OF PRES
The pathophysiology of PRES is not fully understood but is usually postulated to involve severe systemic arterial hypertension disrupting cerebral Proceedings of Singapore Healthcare  Volume 23  Number 3  2014 autoregulation thereby causing hyperperfusion, endothelial cell injury, blood brain barrier disruption and formation of vasogenic oedema 12 . Other proposed mechanisms include endothelial dysfunction from direct insult and toxicity 13 , such as in cases where cytotoxic therapies are used, or a state of endothelial activation 12, 14 as in eclampsia, sepsis or tumour lysis syndrome. With anti-angiogenic therapies, PRES is most likely a consequence of systemic arterial hypertension, a well-known adverse effect of this drug class, as well as endothelial dysfunction from direct injury.
Regardless of the underlying mechanism, it is believed that they all lead to dysfunction at the level of the blood brain barrier 15 with resultant vasogenic oedema. With its relative lack of perivascular sympathetic innervation and hence a more rapid loss of protective vasoconstriction [16] [17] [18] [19] , the posterior cerebral circulation is most frequently affected 16, 17 .
PRESENTATION, DIAGNOSIS AND DIFFERENTIALS OF PRES
Patients typically present with an insidious onset of headache, altered consciousness (including confusion, lethargy, somnolence or even coma), visual disturbances and seizures 20 . Hypertension is frequent but not invariable 21, 22 . Visual symptoms may include blurred vision, scotoma 15 , hemianopia 23 , visual hallucinations 15 , visual neglect 23 or cortical blindness 15, 17 but fundoscopic examination is almost always normal except for occasional signs of acute or chronic systemic arterial hypertension such as optic disc oedema, hemorrhages or exudates 13, 15 .
The diagnosis is made from the clinical picture supported by characteristic radiological findings. Typical neuroimaging findings are symmetrical white matter oedema in the posterior cerebral hemispheres, particularly the parieto-occipital regions 13, 20 . These may be seen on computed tomography scans 24 but are best depicted by brain magnetic resonance imaging (MRI) 25 with T2weighted ( Fig. 1a ) and fluid-attenuated inversion recovery (FLAIR) ( Fig. 1b) showing cortical and subcortical hyperintensities ( Fig. 1) [11] [12] [13] [14] 16, 22, 23 corresponding to areas of vasogenic oedema. With growing experience with PRES, however, previously thought atypical radiological findings including unilateral asymmetrical involvement of other parts of the brain such as the basal ganglia, cerebellum Proceedings of Singapore Healthcare  Volume 23  Number 3  2014 and brain stem have also been described and no longer preclude the diagnosis of PRES in an appropriate clinical context 26 . With treatment, typical findings of PRES on neuroimaging are expected to resolve within days to weeks. Failure of response to treatment of PRES should prompt consideration of other diagnoses.
Differential diagnosis of PRES includes a wide spectrum of neurological diseases such as ischaemic stroke, infectious encephalitis, cerebral venous thrombosis, central nervous system vasculitis or neoplasm 16, 23 . Ischaemic stroke, in particular bilateral posterior cerebral artery infarctions ("top of basilar syndrome"), is an important differential to distinguish from PRES. The presentation may be similar, however treatment differs greatly and misdiagnosis may lead to administration of procedures such as thrombolytic therapy inappropriately. In this respect, diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences on MRI are helpful. Ischaemic stroke results in cytotoxic oedema rather than the vasogenic oedema seen in PRES. In DWI, vasogenic oedema has normal or decreased signal intensity, differentiating it from cytotoxic oedema which shows up as increased signal. On the other hand, vasogenic oedema shows increased signal while cytotoxic oedema decreased signal on ADC maps 17, 22 .
MANAGEMENT Even though PRES is usually non-fatal with complete resolution of radiological changes and neurological signs and symptoms in majority of the cases, it can occasionally lead to permanent neurologic disability or even death 21, 22, 27 . Therefore early recognition and institution of treatment is crucial to ensure the best outcome. This is achieved primarily by discontinuation of the precipitant and control of the blood pressure with antihypertensive agents.
In patients with PRES associated with malignant hypertension, the initial aim of treatment is to rapidly lower the diastolic pressure to about 100 to 110 mmHg, within two to six hours, with the maximum initial fall not exceeding 25 percent of the presenting value 28, 29 . More aggressive lowering of the blood pressure below the autoregulatory range 30 may be harmful leading to ischaemic stroke or coronary events. In patients who do not present Fig. 1 . Contrast-enhanced MRI brain imaging: a. T2-weighted; b. T2-FLAIR of patient with metastatic colorectal cancer who developed PRES following treatment with an anti-VEGF antibody and chemotherapy. Magnetic resonance imaging was performed at presentation and 8 days later. As other factors such as electrolyte disturbances, fluid overload, uraemia and sepsis can potentially exacerbate neurologic deterioration in PRES or share similar symptoms 27 , these should also be aggressively screened for and treated concurrently.
Anti-angiogenic drug Underlying Disease Case Report References
In the case of PRES related to anti-angiogenic agents, cytotoxic and immunosuppressive therapy, prompt removal of causative agent is recommended and re-introduction should be avoided due to risk of recurrence of PRES 21, [31] [32] [33] .
CONCLUSION
With the increased use of anti-angiogenic therapy in cancer treatment, it is important that clinicians are aware of and familiar with PRES being one of its uncommon but significant side effects. As clinical manifestations of PRES are often nonspecific, a high index of suspicion is required for early recognition, institution of appropriate investigations and management to achieve good outcomes, particularly when simple measures such as control of hypertension and withdrawal of the inciting agent usually leads to resolution of PRES. Anti-angiogenic agents are a standard of care in the management of various cancers. The risks of significant toxicity are relatively low and must be balanced against the proven efficacy of these treatments to improve patient survival. Therefore they should continue to be used with appropriate patient counselling and selection in conjunction with physician vigilance.
